The Angiosarcoma Project reported KDR mutations at a rate significantly higher than expected by chance, with a 25.5% recurrence rate (26) - notably, 89% of KDR missense mutations observed in primary breast AS samples. This evidence concerns the gene KDR and angiosarcoma.